White Paper BPLM Why Biopharma Lifecycle Management?The Biopharmaceutical industry has big ambitions to accelerate the move towards industry 4.0. In this white paper we explore some of the major bottle- necks in the development lifecycle and the current barriers to effective digital transformation. We conclude by exploring the role effective BioPharmaceutical Lifecycle Management BPLM platforms will play in accelerating time to market for vaccines and therapies. The global events surrounding the 2020 SARS-CoV-2 pandemic have put a renewed focus on the time and cost of bringing new therapeutics and vaccines to patients. Recent research highlighted that the average cost to develop a new drug sits at $1.3 Billion. 1 With timelines ranging from 8 to 16 years and attrition rates

Join for free to read